Phase 4 N=206 Randomized Single-blind Treatment

Efficacy of Liposomal Bupivacaine Versus 0.25% Bupivacaine for Laparoscopic Urologic Surgery

Pain, Postoperative

Bottom Line

View on ClinicalTrials.gov: NCT02222129 ↗

Enrolled (actual)

206

Serious AEs

0.0%

Results posted

Apr 2015

Primary outcome: Primary: Total Opioid Consumption Measured in Intravenous Morphine Equivalents During the Postoperative Hospital Stay — 17.3; 15 mg (morphine equivalents) — p=0.39

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Bupivacaine (Drug); liposomal bupivacaine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Knight, Richard, M.D.
Primary completion: Dec 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Total Opioid Consumption Measured in Intravenous Morphine Equivalents During the Postoperative Hospital Stay	17.3; 15	0.39
SECONDARY Visual Analog Pain Scores.	—	—
SECONDARY Length of Hospital Stay.	—	—
SECONDARY Time to First Opioid Use.	—	—

Summary

A prospective, randomized comparison of bupivacaine to liposomal bupivacaine given by local injection at all the wound sites in patients undergoing robotic-assisted or laparoscopic urologic surgeries in an effort to determine which method reduced postoperative opioid use the most.

Eligibility Criteria

Inclusion Criteria

At least 18-years-old, undergoing laparoscopic urologic surgery.

Exclusion Criteria

Pregnant and/or nursing mothers.
Allergy to bupivacaine.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02222129). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.